The recent U.S. Food and Drug Administration approval of lifileucel, the first commercial tumor-infiltrating lymphocyte (TIL) therapy for advanced melanoma, marks a significant breakthrough in cancer ...

Iovance Biotherapeutics recently received FDA clearance to proceed with an investigational new drug application for IOV-5001, a next-generation IL-12 tethered tumor infiltrating lymphocyte therapy, ...

Please provide your email address to receive an email when new articles are posted on . The addition of pembrolizumab to TIL therapy improved response rates among individuals with metastatic ...

Next-Generation Platform Expands into Solid Tumors Representing 100,000+ U.S. Deaths AnnuallySAN CARLOS, Calif., June 01, 2026 (GLOBE NEWSWIRE) ...

Lymphedema Treatment Act: A Critical Step for Cancer Survivors, but Unresolved Equity Gaps Persist Patients with advanced melanoma resistant to immune checkpoint or BRAF/MEK inhibitors have treatment ...

Leveraging tumor organoids to model drug response in clear cell renal cell carcinoma. % Reactive Fragments 65.2 ± 26.8 43.0 ± 46.2 % CD56 + of TIL Expansion 14.1 ± 26.2 9.8 ± 4.6 % CD3 + of TIL ...

Researchers at Moffitt Cancer Center have found that tapping into the body's own immune system and activating a type of immune cell known as B cells, could be the key to boosting the effectiveness of ...

Tumor-infiltrating lymphocytes (TILs) are immune cells that naturally recognize and penetrate tumors to kill cancer cells, making them a promising approach for treating solid tumors. This potential ...

In a new study, TILs significantly predicted both distant disease-free survival and overall survival in early ERBB2-positive breast cancer. TIL levels ≥20% were associated with better outcomes when ...

Both Agenus AGEN and Iovance Biotherapeutics IOVA are small-cap companies focused on next-generation cancer immunotherapies ...